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Abstract
Background: Gliomas are the most common type of primary brain tumours, and in this group glioblastomas
(GBMs) are the higher-grade gliomas with fast progression and unfortunate prognosis. Two major aspects of
glioma biology that contributes to its awful prognosis are the formation of new blood vessels through the process
of angiogenesis and the invasion of glioma cells. Despite of advances, two-year survival for GBM patients with
optimal therapy is less than 30%. Even in those patients with low-grade gliomas, that imply a moderately good
prognosis, treatment is almost never curative. Recent studies have demonstrated the existence of a small fraction
of glioma cells with characteristics of neural stem cells which are able to grow in vitro forming neurospheres and
that can be isolated in vivo using surface markers such as CD133. The aim of this study was to define the
molecular signature of GBM cells expressing CD133 in comparison with non expressing CD133 cells. This molecular
classification could lead to the finding of new potential therapeutic targets for the rationale treatment of high
grade GBM.
Methods: Eight fresh, primary and non cultured GBMs were used in order to study the gene expression signatures
from its CD133 positive and negative populations isolated by FACS-sorting. Dataset was generated with Affymetrix
U133 Plus 2 arrays and analysed using the software of the Affymetrix Expression Console. In addition, genomic
analysis of these tumours was carried out by CGH arrays, FISH studies and MLPA;
Results: Gene expression analysis of CD133+ vs. CD133- cell population from each tumour showed that CD133+
cells presented common characteristics in all glioblastoma samples (up-regulation of genes involved in
angiogenesis, permeability and down-regulation of genes implicated in cell assembly, neural cell organization and
neurological disorders). Furthermore, unsupervised clustering of gene expression led us to distinguish between two
groups of samples: those discriminated by tumour location and, the most importantly, the group discriminated by
their proliferative potential;
Conclusions: Primary glioblastomas could be sub-classified according to the properties of their CD133+ cells. The
molecular characterization of these potential stem cell populations could be critical to find new therapeutic targets
and to develop an effective therapy for these tumours with very dismal prognosis.
* Correspondence: adolsan@usal.es
7Department of Medicine, University of Salamanca, Spain
Full list of author information is available at the end of the article
Garcia et al. BMC Cancer 2010, 10:454
http://www.biomedcentral.com/1471-2407/10/454
© 2010 Garcia et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
The cancer relapse and mortality rate suggests that cur-
rent therapies do not eradicate all malignant cells. In
this sense, there is increasing evidence that many types
of cancer contain their own stem cells: cancer stem cells
(CSCs), which are characterized by their self-renewing
capacity and differentiation ability [1]. The study of hae-
matological disorders shed light on the relationship
between cancer and stem cell compartments, and the
mechanisms by which CSCs might appear and change
during the progression of the disease [2,3]. However, the
evidence for the existence of CSCs in solid tumours has
been more difficult to find because of the lack of speci-
fic cell surface markers. During the last years, different
cancer cell subpopulations from selected types of
human solid cancers have been identified (breast [4],
brain [5-7], colon or colo-rectal [8-10], head and neck
[11] and pancreatic cancer [12]). These authors, through
the use of cell culture, FACS and/or MACS methods,
have been able to identify different cell populations
within the tumour showing hallmarks of stem cells. This
stem cell potential, including self-renewal and lineage
capacity, was demonstrated by serial transplantation
experiments in animal models. Specifically, the investi-
gation of solid tumour stem cells has gained momentum
particularly in the area of gliomas, the most common
type of brain tumours. In this group, glioblastoma multi-
forme is the highest-grade glioma [GBM; grade IV] and
is manifested by morphological, genetic and phenotypic
heterogeneity [13-15]. Two major aspects of glioma biol-
ogy that contributes to its awful prognosis are the for-
mation of new blood vessels through the process of
angiogenesis and the invasion of glioma cells, the hall-
marks of GBM [16]. In addition, these abnormal blood
vessels have also been shown to create a vascular niche
that houses glioma stem cells [17].
Despite of the recent advances, two-year survival for
GBM patients with the most favourable treatment is
less than 30%. Even in those patients with low-grade
gliomas therapy is almost never curative. Recent studies
have confirmed the existence of a small portion of
glioma cells with characteristics of neural stem cells [1].
In general, this fraction is characterized by its neuro-
sphere-forming ability, its strikingly increased drug
resistance, and finally, by its ability to express surface
markers that are oftenly used for their FACS-based iso-
lation [5,6]. With the implantation during this last dec-
ade of the NS forming assay as a robust method for the
isolation of neural stem cells [18], it has become widely
accepted that adult mammalian brain harbours a pool
of NSCs responsible for the persistent neurogenesis,
seen in limited adult brain regions, such as the
sub-ventricular zone, olfactory bulb and hippocampal
dentate gyrus [19].
However, it should be borne in mind that the NS
assay is not the most suited source of primary adult
stem cells for transcriptomic analysis since cells are
selected based on its in vitro proliferation capacity in
the presence of cytokines and growth factors in their
cell cultures such as EGF and FGF.
At the end of twenty century, two independent labora-
tories could identify and isolate human central nervous
system stem cells using antibodies against CD133
[20,21]. This protein, named prominin, identifies a sub-
set of human foetal brain cells distinct to human hae-
matopoietic stem cells, which are also CD133+ but are
also CD34-bright [22]. This subset of human CD133+
fetal brain cells is capable of neurosphere initiation, self-
renewal, and multilineage differentiation at the single-
cell level [20]. The CD133+ cells can differentiate
in vitro to neurons and glial cells, and their transplanta-
tion into the lateral ventricles of newborn NOD-SCID
mouse brains resulted in specific engraftment in numer-
ous sites of the brain [20,21,23].
The CD133 marker is a five-transmembrane protein
which is expressed in different type of progenitors as
human fetal brain cells or human hematopoietic stem
cells [20-22]. In brain tumours the proportion of these
CD133+ cells represent a minority of the tumour cell
population and are also capable to initiate tumour for-
mation in vivo. Although it have also been reported that
a proportion of these tumours could be maintained by
CD133- cells [24], there are several evidences showing
how this small fraction of CSC which forming NS, can
also be isolated using CD133 as a selection marker [6].
In the present study, we have analysed thoroughly the
molecular signature of eight fresh primary GBMs focused
on its CD133 positive and negative cells. Importantly, all
tumours were studied before any treatment of the patient
and without previous tumour cell culturing. In addition
to the expression analysis of the FACS-sorted cells, we
have also performed genome-wide analysis by CGH-
arrays, FISH studies at PTEN and EGFR loci, and MLPA
at the MGMT promoter. The results obtained concluded
that the gene expression signature of CD133+ discrimi-
nate common genes to all samples involved in two main
characteristic pathways deregulated in GBMs, angiogen-
esis and invasiveness. However, CD133+ gene expression
profile also allowed distinguishing between two different
GBM subtypes in higher or lowering proliferative
tumours. The molecular biology and the expression sig-
nature of these CD133+ cells that drive and support the
tumour growth will shed light on the development of
fresh and specific treatment strategies.
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Methods
Samples, flow cytometry and sorting assays
Fresh tumours from eight patients affected of primary
GBM without any previous treatment were collected (clinic
and pathologic features are summarized in Table 1).
Patients’ diagnostic were confirmed by the Pathology Facil-
ity from the University Hospital of Salamanca, Spain. At
the surgical extraction moment, a vast proportion of each
tumour was processed to isolate the CD133+ and CD133-
cells without previous cell culture. Single-cell suspensions
were prepared from individual tumours by standard proce-
dures. We decided to undergo a mechanical disaggregation
of tumour samples due to the softness of brain samples,
avoiding enzymatic stress that could change the cell surface
and even their gene expression. Briefly, tumours were care-
fully sliced and forced through a 70 μm single-cell filter
into the Ca++/Mg++ free phosphate-buffered saline by
applying gentle pressure using the piston of a disposable
plastic syringe, All single-cells were used for staining. Cells
were immunophenotyped using human CD133/2 (293C3)
phycoerythrin conjugated antibody (MACS, Miltenyibio-
tec). Mature red cells were depleted by hypotonic lysis
solution (0.38% ammonium chloride for 15 minutes on ice)
before staining. Cells suspended in Ca++/Mg++ free phos-
phate-buffered saline supplemented with 1% fetal calf
serum were labelled with this antibody (approximately
1 μg/106 cells) for 30 minutes on ice. Cell fluorescence was
analyzed and sorted using the FACS Aria sorter (Becton
Dickinson, New Jersey, USA). CD133 antibody was tested
previously in human bone marrow (BM) cells in which
CD133 positive cells were described before (Figure 1). BM
cells were incubated with CD133 and CD34 antibodies
(Pharmingen), sustained in studies that demonstrate that
antibodies against CD133 also identified a subset of
CD34bright BM hematopoietic stem cells [22]. Cell viability
was assessed by propidium iodide exclusion (5 μg/mL;
Sigma) using flow cytometry.
Expression arrays
We studied a dataset generated with Affymetrix U133
Plus 2 arrays (Affymetrix, Santa Clara, CA, USA) in 8
gliomas. Results from this expression analysis have been
deposited at GEO [25] with accession number GSE18015.
Isolated cells (CD133+ and CD133- from each tumour)
using sorting methods were collected in separated vials
containing RNA Later (Qiagen, Chatsworth, CA, USA).
Total RNA was extracted from CD133+ and CD133-
sorted cells using Trizol (Invitrogen, Carlsbard, CA) mak-
ing a total of 16 samples (8 positives and 8 negatives).
The integrity of the RNA was confirmed with the Agilent
Bioanalyzer 2100 using the RNA 6000 Pico kit (Agilent).
We used the GeneChip® Expression 3’ Amplification
Two-Cycle Target Labelling kit (Affymetrix, Santa Clara, Ta
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CA, USA) to label the RNA following the manufacturer
protocol. The cRNA was hybridized to Affymetrix
Human U133 Plus 2 arrays according to the manufac-
turer protocol. Briefly, double-stranded cDNA was
synthesized routinely from less than 1 microgram of total
RNA primed with a poly-(dT) -T7 oligonucleotide. The
cDNA was used in an in vitro transcription reaction in
the presence of T7 RNA polymerase and biotin-labelled
modified nucleotides during 16 hours at 37°C. Biotiny-
lated cRNA was purified and then fragmented (35-200
nucleotides), together with hybridization controls and
hybridized to the microarrays for 16 h at 45°C. Using the
GeneChip Fluidics Station 450 (Affymetrix), the biotin-
labelled cRNA was revealed by successive reactions with
streptavidin R-phycoerythrin conjugate, biotinylated anti-
streptavidin antibody and streptavidin R-phycoerythrin
conjugate. The arrays were finally scanned in an Affyme-
trix GeneChip Scanner 7G Plus.
Preliminary data analysis was conducted using the
software of the Affymetrix Expression Console from
AGCC suite (Affymetrix GeneChip Command Console,
version 1.1) following the statistical procedures
described in the Affymetrix: Expression Console User
Guide, selecting the 3’ Expression Analysis guidelines
for MAS5 and PLIER algorithms in two independent
steps. MAS5 calculated the present call index for each
of the 54,675 probe sets on the chip (settings used were
standard for the HG U133 Plus 2 array: alpha1 = 0.04,
alpha2 = 0.06, Tau = 0.015, TGT = 500). This present
call index was used to select 245 probe sets having Pre-
sence index through the 16 analyzed samples. PLIER
algorithm was used to calculate the normalized expres-
sion values of the probe sets (using quantile normaliza-
tion and PM-MM background correction methods).
Statistical analysis and post-processing were performed
using TIBCO Spotfire 9.1 (TIBCO Software Inc., Palo
Alto CA, USA).
Multidimensional Scaling Analysis of CGH and Gene
Expression data for the eight samples was performed
using the multivariate statistics options of the Simfit
Package (Version: 6.1.10 © W. G. Bardsley, University of
Manchester, http://www.simfit.man.ac.uk/).
Network analysis was performed mapping the results
on the IPA 8 knowledge database (Ingenuity Pathway
Analysis).
CGH array
DNA from each fresh-frozen sample was extracted with
the standard phenol-chloroform method and normal
DNA was prepared from human placenta of healthy
donors. DNAs were quantified using the Nanodrop spec-
trophotometer. DNA quality was assessed by the 260:280
ratio and its integrity by agarose gel ethidium bromide
visualization. Genomic-wide analysis of DNA copy num-
ber in each patient was performed using CGH based array.
Due to the low proportion of CD133 positive cells in each
tumour sample, CGH array only was performed using
genomic DNA from the bulk tumour. Slides containing
3296 BACs were produced in “Centro de Investigación del
Cáncer” (Salamanca, Spain). The particular bacterial artifi-
cial chromosome (BAC) and P-1 derived artificial chromo-
some set used to produce this array is distributed to
academic institutions by the Welcome Trust Sanger Insti-
tute (Cambridge, United Kingdom) and contains targets
spaced at ≈ 1 Mb density over full genome, a set of subte-
lomeric sequences for each chromosome arm and a few
hundred of probes selected for their involvement in onco-
genesis. The clone content is available in the “Cytoview”
windows of the Sanger Institute mapping database site,
Ensembl (http://www.ensembl.org/). According to this
database, clones were ordered along the chromosomes.
For the array, 10 simultaneous hybridizations of normal
male versus normal female and placenta (DNA reference)
was performed to define the normal variation for the log2
ratio. Cy5/Cy3 intensity ratios of every spot were con-
verted into log2 ratios. The log2 ratio of each clone was
Figure 1 FACS sorting of glioblastoma cells using CD133 and
CD34 antibodies. Control samples from human bone marrows
incubated with CD133 antibody. 1: Total cellularity; 2: Gate CD34
without CD133-PE; 3: Gate CD34 with CD133-PE.
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normalized to the median log2 ratio of the ten control
hybridizations, after which the median of triplicate spots
was calculated. Data from two-colour hybridizations for
both DNA were normalized using the corresponding
GEPAS module DNMAD [26]. Regions of copy number
gained and lost for the BAC array-CGH data were identi-
fied by creating sample specific thresholds. Reference copy
number polymorphisms were carefully revised in all data
sets. Therefore every clone on the array was compared
with ‘Database of Genomic Variants’ (http://projects.tcag.
ca/variation/) [27,28]. For unsupervised clustering analysis,
we converted the relative ratio value for each BAC clone
to a score of 1 (gained/amplified), 0 (no change), or -1
(lost) based data obtain by the binary segmentation
method described by Olshen et al. [29] and analyzed data
with Cluster and TreeView of GEPAS (Multi Experiment
Viewer 4.0) based on the average linkage method with the
Pearson uncentered metric correlation. Statistical evalua-
tion was carried out using the SPSS 15.0 statistical soft-
ware (Chicago, Illinois, USA). All P-values reported were
two-sided and statistical significance was defined as
P-values < 0.05. Complementary details on this method
are summarised in Additional file 1.
Fluorescence in situ hybridization
Dual-probe fluorescence in situ analysis were performed
with locus-specific probes for centromere 7/EGFR gene
and centromere 10/PTEN gene (Vysis, Dowerners
Grove, IL). FISH studies were carried out following
well-established methods [30]. Polysomies (chromoso-
mal gains) were defined as more than 10% of nuclei
containing three or more CEP signals. Specimens were
considered to have an amplification of EFGR when
more than 10% of CD133 negative tumour cells exhib-
ited an EGFR/CEP7 ratio >2 or inestimable tight clusters
of signals of the locus probe.
Real-Time PCR
CD133+ and CD133- amplified RNA samples were
reverse-transcribed to cDNA. PCR reactions were per-
formed using equal amounts of cDNA as template. SYBR
Green PCR Master mix (Applied Biosystems, USA) was
used for template amplification using standard protocol
with specific primers for each of the transcripts examined
[Additional file 2: Supplemental Table S1]. Incorporation
of the SYBR Green dye into PCR products was moni-
tored in real time with an ABI PRISM 7000 sequence
detection system (Applied Biosystems). SDS system soft-
ware was used to convert the fluorescent data into
threshold cycle (Ct) at which exponential amplification of
products begins. The differences in the Ct values (dCt)
between the transcript of interest and endogenous con-
trol (GAPDH) were used to determine the relative
expression of the gene in each, adapted from [31]. qPCR
was performed using specific primers to corroborate
expression array result for several genes of those 245 pre-
sented probes [Additional file 3: Supplemental Figure S1].
MS-MLPA analysis
MLPA analysis was performed using SALSA MLPA Kit
ME011 and executed as described by the manufacturer
(MRC-Holland) with minor modifications in order to
detect MGMT promoter methylation. Briefly, 5 μl of
each tumour DNA was denatured and subsequently
cooled down to 25°C. After addition of the probe mix,
the sample was denatured and probes were allowed to
hybridize. Sample was ligated with or without HhaI
digestion, resulting in ligation of the only digested
sequences. PCR amplification was performed using as
template both ligation products (50 μl PCR volume con-
taining 10 μl of the ligation reaction). Agarose gel elec-
trophoresis was used to check MLPA efficiency. Then,
PCR reaction fragments were separated by capillary gel
electrophoresis (ABI 3739, Applied Biosystems) and
quantified using the Genemapper software (Applied Bio-
systems). MS-MLPA processing was performed using
Coffalyser analysis tool developed at MRC-Holland
(http://www.mlpa.com) and performed as described by
Jeuken et al [32].
Results
Patients with higher number of CD133+ cells could
present resistance to the treatment
In order to check the functionality of the CD133 anti-
body and the FACS, we firstly tested the methodology
in a human bone marrow sample. In normal conditions,
CD133 antibody also identifies a subset of bone marrow
stem cells, which are also CD34 positives. Figure 1
shows how CD133 antibody identifies a pool of well-
defined human CD133+/CD34+ cells. Using the same
procedure, we sorted the CD133 positive population
from each fresh GBM sample without previous cell cul-
ture (Figure 2). Table 1 shows the absolute number and
percentage of CD133+ cells obtained from each sample
as well as clinical-biological parameters of each patient.
It is interesting to note that only those two patients
with higher number of CD133+ cells (more than 10000
cells) did not response to the chemotherapy. Interest-
ingly this correlation, high CD133+ cell number and
resistance to therapy, has also been observed in patients
and in GBM cultured cells [33-35] which further vali-
date our approach.
EGFR, PTEN and MGMT genes are altered in the GBM
primary samples
The implication of different genetic alterations in the prog-
nosis of primary glioblastoma such as EGFR amplification,
PTEN deletion or MGMT promoter methylation has been
Garcia et al. BMC Cancer 2010, 10:454
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previously described. As EGFR, PTEN and MGMT genes
are usually altered in primary GBMs, we decided to corro-
borate the primary nature of our samples by checking for
the existence of these alterations in the bulk tumour cell
population of GBMs by FISH analysis and MLPA assay.
EGFR amplifications were detected in 3 of 8 samples and
PTEN deletions in 6 of 8 samples. Additionally, we also
detected MGMT promoter methylation but none of these
variables were significantly related to the biological features
of the patients (see Table 1 and Figure 3B). It is important
to remark that the number of cases studied is probably too
low to find this kind of correlation.
Common genomic imbalances identify patients with
higher number of CD133+ cells without treatment
response
In addition to the expression studies, we analyzed the
genomic profile by CGH in the bulk tumours. All P-
values reported were two-sided and statistical signifi-
cance was defined as P-values < 0.05. In more than 50%
of cases the gains affected to chromosomal regions
located at 1q31-q42, 3q25, 4p15, 6p21-6q23, 7p21, 7q21,
9p21, 9q22, 11q22, 12q21 and 18q12. The losses were
located on regions at 1p36, 1p13, 2p23, 5p15, 10q24.16,
12q13, 13q14, and 17p were also affected on more than
50% of cases [Additional file 4: Supplemental table S2].
Two major genetic groups emerge from the unsuper-
vised clustering of CGH data (Figure 3A). Significantly,
the only two cases with higher number of CD133+ cells
and without treatment response, samples G4 and G11,
grouped together. This cluster was characterized with
common genomic rearrangements with gains on
3p21.31, 6p21, 6q25, 7p14.2, 9q22, 15q11, 20q13 and
22q13 chromosomes.
CD133+ vs. CD133- gene expression analysis divided
GBMs in 2 different groups
Although the number of samples is not very large, the
main feature that distinguishes this work from previous
studies [36,37] resides on the ex-vivo study of GBM cells
Figure 2 FACS sorting of GBM cells using CD133 antibody. Dot plot representation of CD133+ and CD133- populations in GBM tumour
samples are shown. CD133+ population is painted in red and CD133- population in green. Percentage of each population is marked (green for
CD133- and red for CD133+ percentage). Tumour sample is illustrated in the upper side of each plot.
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that were analysed. Using direct sorting of CD133+ cells
without previous cell culture led us to obtain a bona fide
primary pool of CD133+ cells. Even when these cells repre-
sent a low percentage in the number of tumour cells, as in
a normal tissue, we were able to isolate and amplify their
RNA (by two rounds of amplification) in order to study
their gene expression signature in comparison to its coun-
terpart population of CD133- from the same GBM tumour.
Data normalized from preliminary analysis was used to
calculate only those probe sets that were present
(as described in the MAS5 algorithm) in all the samples
(16 arrays from 8 GBM; hybridization per cell popula-
tion). Results from this expression analysis have been
deposited at GEO [25] with accession number GSE18015.
A final list of 245 probe sets was obtained according
to these parameters. Initially, unsupervised clustering of
245 gene list using GEPAS Release v3.1 software (http://
gepas3.bioinfo.cipf.es/) allowed us to examine the first
classification of these GBMs. Importantly, GBM samples
were ordered in two main groups (Figure 4). Samples
G9 and G11 were grouped together and apart from the
rest. However, their only common biological characteris-
tic was their tumour location. G9 and G11 presented a
parietal location versus the temporal or local locations
presented by the remaining tumours (Table 1).
Commonly up-regulated and down-regulated genes in
CD133+ GBMs
Following the initial classification proposed by SOTArray
of GEPAS, we were able to discriminate a minor group of
genes commonly up (19 genes) and down-regulated
(22 genes) in all samples (CD133+/CD133-) (Tables 2
and 3). Common up-regulation of genes such as
COL1A1, COL1A2, PGF, LRRFIP1, TMEFF2 or TGFB1
Figure 3 CGH array and MGMT promoter methylation assays in
GBM samples. A) Unsupervised cluster analysis of CGH data from 8
primary GBMs. Each column represents one case and each row
represents one BAC clone. We assigned values of 1, 0 and -1 for
gain, no change and loss, respectively. Losses are in green and
gains in red. P-values < 0.05. B) Ideogram showing MGMT promoter
methylation.
Figure 4 Unsupervised clustering of CD133+ cells vs. CD133-
cell gene expression signature from each tumour sample show
2 main GBM groups. To molecularly characterize glioblastoma
stem cells of GBM tumours, we compared the gene expression
profiles of purified CD133+ cells from GBM patients versus CD133-
cells from each patient. Each gene (identified at right) is
represented by a single row of coloured boxes; each patient is
represented by one single column. Data are displayed by a colour
code where red indicates over-expression in CD133+ fraction versus
CD133-cells. A group of genes over-expressed for almost all samples
are grouped in the bottom. SOTArray tool from GEPAS Release v3.1,
let us to classify CD133+ vs. CD133- cells from each tumour in 2
mainly groups: G9, G11 and the rest.
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suggested an important role of this pool of cells in blood
vessel formation, angiogenesis, permeability and prolif-
eration pathways, essentials functions in tumour progres-
sion [38-40] (Figure 5). On the other hand, the group of
genes commonly down-regulated in all CD133+ vs.
CD133- cells (that means, over-expressed in the CD133-
compartment) were strikingly related to cell assembly,
neural cell organization and molecular pathways altered
in neurological disorders. That is the case of, GNB2L1,
DPYSL2, TUBA1A or CFL1, all of them important players
in cell migration, morphology and actin polymerization,
in brief, motility of neural differentiated cells (Figure 6).
Table 2 Common up-regulated genes in CD133+ vs.CD133- GBM cells
Gene symbol Gene name Probe set
COL1A1 Collagen, type I, alpha 1 1556499_s_at
TGFBI Transforming growth factor, beta-induced, 68 kDa 201506_at
C10orf104 Chromosome 10 open reading frame 104 224667_x_at
UACA Uveal autoantigen with coiled-coil domains and ankyrin repeats 236715_x_at
C14orf153 Chromosome 14 open reading frame 153 232814_x_at
OCIAD1 OCIA domain containing 1 239748_x_at
CMBL Carboxymethylenebutenolidase homolog (Pseudomonas) 234981_x_at
PDE4C Phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 dunce homolog, Drosophila) 206792_x_at
DBT Dihydrolipoamide branched chain transacylase E2 205370_x_at
LRRFIP1 Leucine rich repeat (in FLII) interacting protein 1 211452_x_at
PRR11 Proline rich 11 219392_x_at
PGF Placental growth factor, vascular endothelial growth factor-related protein 215179_x_at
ZNF160 Zinc finger protein 160 214715_x_at
SEPP1 Selenoprotein P, plasma, 1 237475_x_at
OPHN1 Oligophrenin 1 206323_x_at
COL1A2 Collagen, type I, alpha 2 202403_s_at
FLJ45803 FLJ45803 protein 238701_x_at
TMEFF2 Transmembrane protein with EGF-like and two follistatin-like domains 2 224321_at
SRGN Serglycin 201859_at
Table 3 Common down-regulated genes in CD133+ vs.CD133- GBM cells
Gene symbol Gene name Probe set
HNRPA3 Heterogeneous nuclear ribonucleoprotein A3 1555653_at
ATP13A5 ATPase type 13A5 1553567_s_at
IQWD1 IQ motif and WD repeats 1 224373_s_at; 224372_at
TUBA1A Tubulin, alpha 1a 209118_s_at
DPYSL2 Dihydropyrimidinase-like 2 200762_at
RAB13 RAB13, member RAS oncogene family 202252_at
MATR3 Matrin 3 214363_s_at
DSTN Destrin (actin depolymerizing factor) 201022_s_at
LDHB Lactate dehydrogenase B 213564_x_at
UBC Ubiquitin C 211296_x_at
CFL1 Cofilin 1 (non-muscle) 200021_at
LOC729548 Similar to ribosomal protein S2 203107_x_at
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 213453_x_at; 212581_x_at; 217398_x_at
LOC388076 Similar to ribosomal protein S8 200858_s_at
RPS19 Ribosomal protein S19 202649_x_at; 213414_s_at
TUT1 Terminal uridylyl transferase 1, U6 snRNA-specific 200689_x_at; 211345_x_at; 211927_x_at
RPSAP15 Ribosomal protein SA pseudogene 15 213801_x_at
LOC390860 Similar to 60S acidic ribosomal protein P0 (L10E) 211720_x_at; 208856_x_at; 201033_x_at
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 208718_at
RPL13A Ribosomal protein L13a 212790_x_at
GNB2L1 Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 200651_at
LOC390861 Similar to cytoplasmic beta-actin 200801_x_at
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Two different GBM groups can be functionally defined
according to the expression pattern of 40 genes
The major group of genes discriminated by the SOTArray
of GEPAS presented a differential gene expression pattern
in two of the eight CD133+ vs. CD133- GBM samples, G4
and G7, in contrast to the remaining cases. In this group,
we found out a cluster of genes clearly over-expressed in
some of CD133+ vs. CD133- GBM samples (G4 and G7)
but repressed in the rest. Specifically, a group of 40 well-
defined genes, classified according to their function, were
able to distinguish between 2 different GBM signatures
(Figure 7) revealing the possible different proliferative
potential in high grade GBM tumours (VIM, GLUL, PLK1,
HUWE1, RPS4X...) (Figure 8 and Table 4).
Discussion
Glioblastomas are the higher-grade gliomas with fast
progression and unfortunate prognosis. Recent studies
Figure 5 Commonly CD133+ cell up-regulated genes participate in angiogenesis, tumour development and neural developmental
disorders. Ingenuity representation and classification by functions of those common up-regulated genes in all CD133+ vs. CD133- cell GBM
samples. Red colour genes are the most positive deregulated and grey one those with a lower over-expression levels in this group. The first
cluster of genes (COL1A1, COL1A2, TGFB1...) has been described largely in angiogenesis and permeability whereas the second cluster (LRRFIP1 and
OPHN1) participates in developmental disorders. Changing transcription pattern of all of them favour tumour development.
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have demonstrated in these tumours the existence of a
small fraction of cancer cells endowed with features of
primitive neural progenitor. Although some observations
pointed out towards the involvement of CD133- cells in
tumour maintenance [24], several studies have involved
the CD133+ cells as the brain tumour initiating cell
[6,41,42]. In any case, studies performed in order to
characterize the glioblastoma stem cell have been car-
ried out using in vitro, cultured tumour cells. While
these cultured cells present the capacity to form NS,
essential pathways in cell/tumour biology could likely be
altered as a direct consequence of the cell culturing
such as cell-cell adhesion, cell-niche junctions, exposure
to mitogen activation, rapid division of the cells etc.
To gain insight into the characterization of these cells,
we examined directly for the first time CD133+ cells by
FACS-based purification from ex-vivo primary tumours
without the intervention of cell culturing or any prior
expansion procedure.
Despite that the cohort of tumours analysed was not
very large, we could find a correlation among clinical
history, response to treatment and genomic alterations
Figure 6 Common CD133+ cell down-regulated genes are involved in cell assembly organization and cancer. Ingenuity representation
and classification by functions of those commonly down-regulated genes in all CD133+ vs. CD133- cell GBM samples. Green colour represents
those genes differentially regulated in CD133+ vs. CD133- that participates in cell assembly, migration and cancer pathways.
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in two samples (G4 and G11). Both of these tumours
showed the highest content of CD133+ cells, the lack of
response to treatment and similar chromosomal altera-
tions (multidimensional scaling analysis reflected rela-
tionship among these parameters). However, this
correlation was not further supported by transcription
profiling of CD133+ and CD133- cells. Indeed, non-
supervised analysis of CD133+ vs. CD133- gene expres-
sion (Figure 4) showed that only G9 and G11 samples
were grouped together and apart from the rest, being
the tumour location the only biological feature able to
distinguish them (see Table 1). Despite of this low num-
ber of samples, multidimensional scaling analysis estab-
lished again a relationship between G9/G11 tumour
location and their gene expression.
To understand the biological properties of the CD133+
compartment, we sought to identify common gene signa-
ture by the comparison of CD133+ vs. CD133- cell popu-
lations. This array-based analysis led us to the
identification of gene profiles with common up-regulated
and down-regulated genes. Up-regulated genes such as
COL1A1, COL1A2, PGF [38] or TGFB1 [43], suggested an
important role of these compartment in blood vessel for-
mation, angiogenesis, permeability and invasiveness, essen-
tial functions in tumour progression [38-40]. Significantly,
most of these up-regulated genes encoded secreted pro-
teins involved in autocrine and paracrine signalling, like
TGFBI, a pleiotropic cytokine that, among other functions,
can induce the dissociation of VE-cadherin junctions
between endothelial cells which could favour mature
tumour or GBM cells migration [43]. Up-regulation of
these genes in putative CD133+ stem cells would help to
increase the mobility of cancer stem cells through the
brain, which is consistent with the high invasive character-
istics of these tumours and their high possibility to colo-
nize the adjacent area. It is also worthy to mention in this
same regard, the importance of the microenvironment in
the stem cell/cancer stem cell maintenance, as has recently
been pointed out with the identification of the perivascular
niche in grade I-IV astrocytomas [44]. Several evidences
suggest that normal neural stem cells, and likely also
neural cancer stem cells, exist within protective niches as
the vascular niches, into which endothelial cells secrete
factors that regulate neural stem cell function [45,46]. This
raises the question of whether CSCs could be located and
regulated by these microenvironments. Calabrese et al.
proposed that the tumour microvasculature generates spe-
cific niche microenvironments promoting the mainte-
nance of CSCs [47]. Recent studies using orthotopic
glioblastoma xenografts suggest that CSCs secrete proan-
giogenic factors that promote the recruitment and forma-
tion of tumour blood vessels [48] that significantly
facilitates brain tumour growth and invasion. Our gene
expression findings in ex-vivo CD133+ isolated cells clearly
support this result.
High expression in the CD133+ compartment of genes
such as LRRFIP1, transcriptional repressor of EGFR [49],
would support the idea of EGFR gene as a secondary
event in the process of GBM development by promoting
infiltration and mediating resistance to therapy. In this
same scenario, the positive regulation of the tumour
suppressor gene TMEFF2 [50] in the potential CD133+
stem cell compartment in these GBMs, could also oper-
ate as a late event in the initiation of neoplastic progres-
sion. In fact, low levels of TMEFF2 and other genes
responsible for tissue or cell assembly in the CD133-
compartment would promote the down-regulation of
cell to cell interactions and junctions, providing a mole-
cular mechanism for the highly invasive nature of the
GBM.
The second group of genes, commonly down-regu-
lated in all CD133+ vs. CD133- cell from human ex-vivo
GBM samples (that means, over-expressed in the
CD133- compartment) were found to be associated to
cell assembly, neural cell organization and neurological
disorders. That is the case of genes such as GNB2L1, an
anchor protein involved in adhesion and migration of
human glioma cells [51], DPYSL2, a promoter of micro-
tubule assembly and neuronal development [52],
TUBA1A [53] or CFL, which controls cell migration and
cell cycle progression [54,55]. This group of genes plays
important roles in cell migration, cell polarity and actin
polymerization (Figure 6). In this same oncogenic sce-
nario, it would be interesting to mention the deregulated
expression of HIF-1 gene. This gene which is down-
regulated in most of the CD133+ samples analysed, is
involved in tumour angiogenesis and cell growth [56],
and could play some role in the later events that drive
tumour progression. In this regard, recent studies have
demonstrated that HIF-1 protein stabilization contribute
to tumour angiogenesis, one of the main characteristics
of primary GBMs [16]. Mutations in metabolic enzymes,
in particular isocitrate dehydrogenase enzymes (IDH1
and IDH2), have been shown to be involved in glioma
development and would facilitate HIF-1 protein stabili-
zation [57,58]. The negative deregulation of the HIF-1
gene that we have observed in most ex-vivo CD133+
cells in this work, also support this idea.
A notable feature of the gene expression pattern of
CD133+ cells was the differential expression of 40 genes
that divide GBM samples in two opposite molecular sig-
natures. The classification of these 40 genes according
to their function (Figure 8 and Table 4) pointed to their
implication in cell growth, cell death, DNA replication,
recombination and, definitively, in cell proliferative con-
trol. Amongst these genes we wanted to emphasize the
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differential expression of the gene coding for vimentin
(VIM), an intermediate filament of the mesenchymal
lineage involved in migration, cell signalling, cancer and
neurological disease [59,60]. Some other genes differen-
tially expressed in this pool of cells CD133+ and also
involved in cancer and neurological disease are RPS4X,
RPS3A or TUBA1B (Table 4). Another relevant member
of the top 40 list of genes was HUWE1, a pleitropic
ubiquitin ligase that participates in a wide variety of bio-
logical functions related to cell proliferation such as cell
growth/death, and DNA replication, and that has been
described to be deregulated in different carcinomas [61]
(see Figure 8 and Table 4). Interestingly, this deregu-
lated gene has also been reported to be an important
Figure 7 Forty differential genes in G4 and G7 samples discriminate between high or low proliferative potential. Unsupervised
clustering and ingenuity pathways representation of 40 differentially expressed genes. A) Unsupervised clustering of this 40 gene list let us to
distinguish 2 well defined and opposite groups. Ingenuity principal represented pathways include B) recombination and repair pathways and C)
cancer and cell compromise. Those GBMs with a positive pattern CD133+/CD133- for this gene expression signature, could present a higher
proliferative potential of their tumour stem cells or, by the opposite, a lower proliferative potential of the mature glioma cells.
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control gene for the proliferation capacity of embryonic
NSC in the mice [62]. GLUL encodes the glutamine
synthetase, a metabolic enzyme required for the mainte-
nance of the energy balance and that when mutated
causes severe malformations and neonatal death [63].
Finally, PLK1, the mitotic kinase par excellence, modu-
lates mitosis entry and promotes cell transformation
upon upregulation as an oncogene [64-66]. These
Figure 8 Forty differentially expressed genes in ex-vivo CD133+/CD133- GBM cells classify these tumours according to their functional
categories. Ingenuity functional classification of 40 differentially expressed genes in primary GBMs discriminate two main groups of GBM
according to their proliferative potential.
Table 4 Functional classification of 40 differentially expressed genes in CD133+ vs.CD133- GBM samples
CATEGORY P-VALUE MOLECULES
Protein Synthesis 1,14E-10-
1,14E-10
EIF2AK4, RPL22, RPS4X, RPS3A, RPL27A, RPL7A, RPL39, RPL23A, RPL41, RPL7
Cancer 1,17E-04-
4,38E-02
HUWE1, TRA2B, VIM, PLK1, TUBA1B, ACTG1, RPL7, TPT1, RPS4X, RPS3A, H3F3A, RPS16, GLUL,
HSP90AA1, CLEC2D
Cellular Growth and Proliferation 1,94E-03-
2,89E-02
HUWE1, PLK1, RPL23A
Cell Death 1,99E-03-
3,52E-02
HUWE1, RPS3A, HSP90AA1, VIM, PLK1
Cell Morphology 1,99E-03-
2,36E-02
VIM
Cellular Assembly and Organization 1,99E-03-
3,71E-02
VIM, PLK1, ACTG1, RPL7
DNA Replication, Recombination, and
Repair
1,99E-03-
3,71E-02
HUWE1, VIM, PLK1
Cell-To-Cell Signalling and Interaction 3,97E-03-9,9E-
03
VIM
Cellular Function and Maintenance 5,49E-03-
2,94E-02
EIF2AK4, HSP90AA1, VIM, ACTG1
Cellular Development 5,95E-03-
1,97E-02
EIF2AK4, HSP90AA1, VIM
Neurological Disease 9,02E-03-
4,28E-02
TPT1, RPS4X, RPS3A, RPL39, VIM, ACTG1, NSMAF, TUBA1B, CALM2
Skeletal and Muscular Disorders 9,02E-03-
9,02E-03
TPT1, RPS4X, RPS3A, VIM, TUBA1B
Cellular Movement 1,38E-02-
1,38E-02
VIM
Gene Expression 2,36E-02-
3,13E-02
PABPC1, PLK1
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differentially regulated molecules must be playing pivo-
tal roles in keeping the tumour cells in a switch-on state
that enables them to survive, proliferate and invade the
surrounding healthy tissue.
In brief, the results obtained in this study revealed the
presence in CD133+ cells from primary glioblastoma of
a common gene expression signature involved princi-
pally in the promotion of proangiogenic and invasive
programs. Additionally, CD133+ gene expression pattern
led us to discriminate between two different GBM sub-
types in higher or lower proliferative tumours. The
molecular biology and the expression signature of these
CD133+ cells that drive and support the tumour growth
will shed light on the development of new treatments to
fight against GBMs.
Conclusions
Ex-vivo analysis of CD133+ primary GBM cells has dri-
ven us to the valid detection of a common gene expres-
sion profile among GBMs principally characterized by
the expression of genes involved in blood vessel forma-
tion, angiogenesis and invasiveness, the main aspects of
glioma biology that contributes to its adverse prognosis.
Besides, data obtained from the analysis of a group of
40 genes differentially expressed in GBM samples sug-
gest that primary GBM can be sub-classified according
to the properties of their CD133+ cells. Differences
between both groups were provided by the proliferative
potential of their CD133+ population (potential tumour
stem cells). We can conclude that molecular characteri-
zation of CD133+ population in primary GBMs could
be critical in the development of new and effective treat-
ments for these tumours with very dismal prognosis.
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